Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2017-02-06 Share Issue/Capital Cha…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of January 31, 2016. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory filing requirement in France, often related to changes in major shareholdings or capital structure transparency. While it touches upon capital structure, it is a specific monthly disclosure of voting rights, which is not explicitly covered by the provided definitions (like SHA for new issues or MRQ for crossing thresholds). Given the nature of a regular, mandatory disclosure of voting rights and share count, it fits best under the general regulatory filing category, RNS, as it is a specific regulatory update that doesn't align perfectly with the other specialized codes like DIV, CAP, or SHA, which imply an action or a comprehensive report.
2017-02-06 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Investor Presentation Classification · 95% confidence The document is a press release dated January 31, 2017, titled "Nanobiotix: 2016 review and 2017 anticipated milestones." It details the company's clinical development progress, corporate events from 2016, and expected milestones for 2017, including clinical readouts and potential market authorization. It also includes a financial calendar listing upcoming results announcements and the Annual General Meeting (AGM) date (June 14, 2017). Since the document summarizes past performance and future outlook, it functions as a comprehensive update for investors, often associated with an Annual Report or a detailed Investor Presentation. However, it is structured as a forward-looking press release providing operational and financial highlights, which aligns closely with the content of an Earnings Release (ER) or a detailed Investor Presentation (IP). Given the depth of clinical and corporate updates, and the inclusion of a financial calendar, it is more substantial than a typical ER but less formal than a 10-K. The presence of the AGM date suggests it might precede or accompany AGM materials, but the content itself is a broad operational review. Since it covers the full year's review and future outlook, and is a formal press release, it best fits the Investor Presentation (IP) category, which covers strategy, financials, and market position in detail, or potentially a comprehensive Earnings Release (ER) if it were quarterly, but since it's an annual review, IP is a strong fit, or potentially a general Regulatory Filing (RNS) if no better fit exists. Comparing it to the definitions, it is a detailed presentation of strategy and progress, making 'Investor Presentation' (IP) the most appropriate classification over a simple 'Earnings Release' (ER) or a general 'Regulatory Filing' (RNS). It is not a formal 10-K, AR, or MDA, but a summary/presentation of that information.
2017-01-31 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 96% confidence The document is titled "Nanobiotix : Bilan 2016 et perspectives 2017" (2016 Review and 2017 Outlook) and details the company's clinical development progress, regulatory milestones (CE marking application), corporate events (financing, management changes), and provides a forward-looking calendar for 2017 financial announcements (Q4 2016 revenue, Annual 2016 results, etc.). This structure—reviewing the past year and outlining the next year's expectations, often released around the time of annual results or just before—is characteristic of an Annual Report or a document closely related to it, but it is not the formal 10-K filing itself. Since it summarizes the full year's activities and financial context, it functions as a comprehensive annual review. However, it explicitly mentions that the full annual results will be announced on April 28, 2017, suggesting this document is a pre-release summary or a detailed operational review preceding the formal financial filing. Given the comprehensive nature covering clinical, corporate, and financial highlights for the full year 2016, it aligns best with the scope of an Annual Report (10-K) or a detailed Interim/Quarterly Report (IR) if it were for a shorter period. Since it covers the full fiscal year (2016) and sets the stage for the next year, it is most closely related to the Annual Report cycle. If it were a formal SEC filing, it would be a 10-K. As a detailed operational review released by a non-US company (Euronext listed) summarizing the year, it functions as the primary annual disclosure document, often categorized as an Annual Report (AR) if it's not the full statutory 10-K, or sometimes an Investor Presentation (IP) if heavily slide-based. Given the depth and focus on the full year's 'Bilan' (Review), it is classified as an Audit Report/Information (AR) as it summarizes the year's performance and is not the formal 10-K, nor is it just an earnings release (ER) or a presentation (IP). It serves as the comprehensive annual summary document. FY 2016
2017-01-31 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITE" (Annual Balance of the Liquidity Contract) dated January 6, 2017, reporting the status as of December 31, 2016. It details the number of shares and cash balance held under a liquidity agreement with a broker (Gilbert Dupont). This type of regular reporting on share repurchase programs or liquidity maintenance activities, which involves the company transacting in its own shares, aligns best with the 'Transaction in Own Shares' category (POS). While it is a periodic report, it is specifically about the execution of a share transaction program, not a general financial report (like 10-K or IR) or a dividend announcement (DIV).
2017-01-06 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table showing the total number of shares and voting rights as of December 31, 2016. This type of periodic disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement, often related to changes in ownership thresholds or general capital structure updates. While it touches upon capital structure, it is a mandatory monthly disclosure of voting rights, which is a specific type of regulatory announcement. Given the options, it is not a full Annual Report (10-K), Interim Report (IR), or a specific transaction like Director's Dealing (DIRS) or Share Issue (SHA). It is a mandatory regulatory disclosure. Since there isn't a specific code for 'Monthly Voting Rights Disclosure', the most appropriate general regulatory filing category is RNS (Regulatory Filings), as it is a mandatory filing with the regulator (AMF) that doesn't fit the more specific categories like DIV, DIRS, or CAP.
2017-01-05 French
Communiqués de mise à disposition de documents / Modalités de mise à disposition document de référence ou de ses actualisations
Report Publication Announcement Classification · 98% confidence The document is titled "Mise à disposition Actualisation du Document de Référence 2015" (Making available the Update to the 2015 Reference Document). It explicitly states that an update to the Reference Document, which now incorporates the semi-annual financial report for H1 2016, has been filed with the AMF (Autorité des Marchés Financiers). The document itself is short (3124 chars) and serves primarily to announce that the updated document is available on the company's website and the AMF website. This fits the definition of a Report Publication Announcement (RPA), as it announces the publication/availability of a regulatory document (the updated Reference Document containing the interim report), rather than being the full, comprehensive report itself (like an IR or 10-K).
2016-12-28 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.